Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 8/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6353328 | 0.88 | ALB (0.81) | ALBALDH1A1MEN1KMT2ATHRB | |
| SCHEMBL6714088 | 0.84 | THRB (0.46) | ALBALDH1A1MEN1KMT2ATHRB | |
| SCHEMBL6709196 | 0.84 | THRB (0.46) | ALBALDH1A1MEN1KMT2ATHRB | |
| SCHEMBL6833959 | 0.84 | ALB (0.49) | ALBALDH1A1MEN1KMT2APOLB | |
| SCHEMBL6835696 | 0.83 | ALB (0.70) | ALBALDH1A1MEN1KMT2ATHRB | |
| SCHEMBL6357224 | 0.81 | ALB (0.66) | ALBALDH1A1MEN1KMT2ATHRB | |
| SCHEMBL6354039 | 0.81 | TP53 (0.69) | ALBALDH1A1GAATP53SMN1; SMN2 | |
| SCHEMBL6359330 | 0.81 | TP53 (0.72) | ALBALDH1A1MEN1KMT2AGAA | |
| SCHEMBL6707651 | 0.80 | ALB (0.67) | ALBALDH1A1MEN1KMT2ATHRB | |
| SCHEMBL6348611 | 0.80 | ALB (0.69) | ALBALDH1A1MEN1KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | ALB 1417/4885ALDH1A1 170/4885MEN1 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.